Lab Session Will Provide Firsthand Experience using the Company's Award-Winning Waterlase All-Tissue Laser

Annual Tequila & Tongue Ties Conference to be held in Scottsdale, AZ, on April 21-22, 2023

LAKE FOREST, Calif., March 14, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced plans to host its annual Tequila & Tongue Ties conference, a gathering of key opinion leaders (KOLs) and dental clinicians to further educate the medical community on tethered oral tissues (TOTs), including lip-ties and tongue-ties in infants and children, which affects a significant number of newborns. TOTs occur when the frenulums, which are the connective pieces of tissues between the tongue and floor of the mouth, or the lip and gum, are short or thick and limit the movement of the lips, cheek, and tongue.

The annual conference, which will be attended by dentists throughout the U.S., will be held in Scottsdale, AZ, on April 21-22, 2023. The relaxed environment will offer a positive educational experience for dental clinicians and feature clinical speakers, including Dr. Ben Curtis, Dr. Linda Murzyn-Dantzer, Dr. Cherish Leung, Dr. Leslie Blackburn, Dr. Amanda Hankins, and Dr. Trudy-Ann Frazer. Additional speakers include Olivia Smith from Elite Dental Medical Billing and Allison Lacoursiere from Clear Coaching, a social media consulting business.

This year's theme will focus on full team implementation of tongue-tie treatment and practice management. BIOLASE will have a variety of doctors speaking on their personal experiences and successes they have had building out a laser tongue-tie program, techniques on using a laser to perform the frenectomy procedure, medical billing and documentation, and social media/marketing consulting. The Company will be providing a laser lab setup, which will give dental practitioners hands-on experience using the Waterlase all-tissue laser with simulated tissues. 

"We are committed to resolving all dental conditions with our award-winning products, especially those that can lead to other serious medical conditions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "We received an overwhelmingly positive response following the initial conference last year. This year's conference allows us to build upon its success to further educate the dental community and discuss best practices to ensure a happy future for tongue-tied children."

Tequila & Tongue Ties is one of the many educational offerings from the Company's successful Waterlase Academy, BIOLASE Education's home for resources, courses, and content related to all-tissue laser education. Other live education offerings include seminars, classroom training focused on specific dental disciplines, and in-office on-demand training. The Company's Waterlase Academy also offers virtual education with live webinars, on-demand webinars, and podcasts. 


BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2021, BIOLASE has sold over 43,300 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at, Facebook at, Twitter at, Instagram at, and LinkedIn at

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

Michael Polyviou / Todd Kehrli
(732) 933-2754 /

Cision View original content to download multimedia: